cellceutix is an emerging bio-pharmaceutical company
focusing in the areas of cancer
and inflammatory disease...
Press Release 11/7/2011

Cellceutix Files Investigational New Drug Application (IND) with FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center
 
 
Cellceutix Eyeing A $5B Annual Market With Potential Caner Research Breakthrough
Read story at : http://seekingalpha.com/article/309676-cellceutix-eyeing-a-5b-annual-market-with-potential-caner-research-breakthrough
 
 
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com
CTIX and CTIC: A Demonstration in Biotech Stock Ticker Confusion
Cellceutix Eyeing A $5B Annual Market With Potential Caner Research Breakthrough
Interview With CEO Of Cellceutix Corporation: Leo Ehrlich
Cellceutix Matriculates to Harvard
Cellceutix Management Outlines Enormous Potential in Exclusive BiotechStockTrader.com Interview
Leo Ehrlich - CFO - featured in interview with CEOCFO
Stu Taylor on Business, April 10, 2010 show
The Salem News: Autism drug tested on rats
Cellceutix makes strides with Kevetrin cancer drug
Interview with George Evans at SmallCapVoice.com
Breast Cancer Awareness Month Draws Investors Too
Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product
IFCR in pact for collaborative research
Cellceutix Corporation has acquired the rights to the blood pressure compound KM 732
Cellceutix signs agreement with Girindus America
Cellceutix Files Patent Application For Its Cancer Compound
Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug